TITLE

Assessment of cardiac diastolic dysfunction in HIV-infected people without cardiovascular symptoms in China

AUTHOR(S)
Luo, L.; Ye, Y.; Liu, Z.; Zuo, L.; Li, Y.; Han, Y.; Qiu, Z.; Li, L.; Zeng, Y.; Li$2, T.-S.
PUB. DATE
December 2010
SOURCE
International Journal of STD & AIDS;Dec2010, Vol. 21 Issue 12, p814
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This study assessed cardiac diastolic dysfunction (DD) in HIV-infected subjects without cardiovascular symptoms in China. Eighty-four HIV-infected patients without cardiovascular symptoms were recruited and compared with 30 HIV-negative control subjects. Cardiac DD was evaluated using echocardiography including tissue Doppler imaging. DD was detected in 47.6% of AIDS patients and 42.8% of HIV-positive patients, which was significantly higher than in HIV-negative controls. After logistic regression analysis, HIV infection was independently correlated with cardiac DD (P < 0.05). Among HIV-positive subjects, logistic regression analysis showed that zidovudine exposure was associated with higher prevalence of DD (P < 0.05). Asymptomatic cardiac DD was observed frequently in HIV-infected subjects. HIV infection itself and zidovudine exposure were correlated with a higher prevalence of cardiac DD.
ACCESSION #
60169766

 

Related Articles

  • Cardiometabolic risk factors among HIV patients on antiretroviral therapy. Kiage, James N.; Heimburger, Douglas C.; Nyirenda, Christopher K.; Wellons, Melissa F.; Bagchi, Shashwatee; Chi, Benjamin H.; Koethe, John R.; Arnett, Donna K.; Kabagambe, Edmond K. // Lipids in Health & Disease;2013, Vol. 12 Issue 1, p1 

    Background: HIV and combination antiretroviral therapy (cART) may increase cardiovascular disease (CVD) risk. We assessed the early effects of cART on CVD risk markers in a population with presumed low CVD risk. Methods: Adult patients (n=118) in Lusaka, Zambia were recruited at the time of...

  • Low CD4+ T Cell Count Is a Risk Factor for Cardiovascular Disease Events in the HIV Outpatient Study. Lichtenstein, Kenneth A.; Armon, Carl; Buchacz, Kate; Chmiel, Joan S.; Buckner, Kern; Tedaldi, E. M.; Kathy Wood; Holmberg, Scott D.; Brooks, John T. // Clinical Infectious Diseases;8/15/2010, Vol. 51 Issue 4, p435 

    Background. Traditional cardiovascular disease (CVD) risk factors, human immunodeficiency virus (HIV) infection, and antiretroviral (ARV) agents have been associated with CVD events in HIV-infected patients. We investigated the association of low CD4+ T lymphocyte cell count with incident CVD in...

  • Reducing the dosage of AZT in children. Pinkowish, Mary Desmond // Patient Care;5/15/1996, Vol. 30 Issue 9, p184 

    Summarizes an article entitled `Randomized Study of the Tolerance and Efficacy of High-Versus Low-Dose Zidovudine in Human Immunodeficiency Virus-Infected Children with Mild to Moderate Symptoms,' by M.T. Brady, N. McGrath, et al, published in issue number 173 of the `Journal of Infectious...

  • MCV clue in zidovudine patient. Page, George E.; H.C.N. // Cortlandt Forum;3/25/95, Vol. 8 Issue 3, p103 

    Comments that an HIV-positive patient with normal corpuscular volume (MCV) is probably not taking his or her zidovudine.

  • Pharmacokinetic Optimisation of the Treatment of Cancer with High Dose Zidovudine. Danesi, R.; Falcone, A.; Conte, P.F.; Tacca, M.D. // Clinical Pharmacokinetics;1998, Vol. 34 Issue 2, p173 

    The thymidine analogue zidovudine is currently used for the treatment of HIV-infected patients, as the early development of the drug as an anticancer agent yielded modest results. A comprehensive preclinical analysis, however, showed that inhibitors of de novo thymidylate synthesis, including...

  • Zidovudine and didanosine for HIV infection in children. Andolsek, Kathryn M. // American Family Physician;1/1/1998, Vol. 57 Issue 1, p132 

    Presents information on the use of zidovudine for children infected with human immunodeficiency virus (HIV) which is usually acquired by perinatal exposure. Recommendation of zidovudine for symptomatic children; Investigation conducted by Englund and associates on the use of zidovudine,...

  • Is AZT affecting my ability to build muscle?. Cohan, Gary R. // Advocate;10/5/93, Issue 639, p34 

    Discusses the possible effect of AZT to the ability of an HIV-positive man to build muscle. Clarification that AZT is not linked to any problem with muscle formation; Citation of a condition known as hypogonadism as the possible ailment affecting muscle development among HIV-infected persons.

  • An Update on Drug Interactions with Zidovudine. Piscitelli, Stephen C.; Polis, Michael A. // AIDS Patient Care & STDs;Sep98, Vol. 12 Issue 9, p687 

    Looks at the drug interaction of Zidovudine in patients with HIV infection. Concomitant medications which alter the plasma concentrations of zidovudine; Categories drug interactions are divided into; Details on the pharmacokinetic drug interactions with zidovudine; How drug interactions can be...

  • Factors associated with, and echocardiographic findings of heart failure among HIV infected patients at a tertiary health care facility in Dar es Salaam, Tanzania. BAKARI, MUHAMMAD; CHILLO, PILLY; LWAKATARE, JOHNSON // Tanzania Journal of Health Research;Apr2013, Vol. 15 Issue 2, p1 

    Cardiovascular diseases, including heart failure are a known complication of Human Immunodeficiency Virus (HIV) infection globally. The objective of this study was to describe factors associated with, and echocardiographic findings of heart failure among HIV infected patients at a tertiary...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics